{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T11:27:11Z","timestamp":1770550031364,"version":"3.49.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,23]],"date-time":"2021-11-23T00:00:00Z","timestamp":1637625600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine Case Reports"],"published-print":{"date-parts":[[2022]]},"DOI":"10.1016\/j.rmcr.2021.101559","type":"journal-article","created":{"date-parts":[[2021,11,26]],"date-time":"2021-11-26T21:33:05Z","timestamp":1637962385000},"page":"101559","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Effect of benralizumab in a patient with uncontrolled severe eosinophilic asthma and comorbid chronic rhinosinusitis with nasal polyps refractory to mepolizumab treatment"],"prefix":"10.1016","volume":"35","author":[{"given":"Adel H.","family":"Mansur","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.rmcr.2021.101559_bib2","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1164\/rccm.201602-0419OC","article-title":"National Heart, Lung, and Blood Institute's severe asthma research program-3 investigators, inflammatory and comorbid features of patients with severe asthma and frequent exacerbations","volume":"195","author":"Denlinger","year":"2017","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.rmcr.2021.101559_bib3","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2147\/JAA.S176026","article-title":"Adverse outcomes from initiation of systemic corticosteroids for asthma: long-term observational study","volume":"11","author":"Price","year":"2018","journal-title":"J. Asthma Allergy"},{"key":"10.1016\/j.rmcr.2021.101559_bib4","series-title":"FASENRA (benralizumab): Summary of Product Characteristics","year":"2021"},{"key":"10.1016\/j.rmcr.2021.101559_bib7","series-title":"XOLAIR (omalizumab): Summary of Product Characteristics","year":"2020"},{"key":"10.1016\/j.rmcr.2021.101559_bib8","series-title":"NUCALA (mepolizumab): Summary of Product Characteristics","year":"2021"},{"key":"10.1016\/j.rmcr.2021.101559_bib12","series-title":"DUPIXENT (dupilumab): Summary of Product Characteristics","year":"2021"},{"key":"10.1016\/j.rmcr.2021.101559_bib14","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0140-6736(16)31324-1","article-title":"Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting \u03b22-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial","volume":"388","author":"Bleecker","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.rmcr.2021.101559_bib15","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/S0140-6736(16)31322-8","article-title":"Benralizumab, an anti-interleukin-5 receptor \u03b1 monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"388","author":"FitzGerald","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.rmcr.2021.101559_bib16","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1056\/NEJMoa1703501","article-title":"Oral glucocorticoid\u2013sparing effect of benralizumab in severe asthma","volume":"376","author":"Nair","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.rmcr.2021.101559_bib17","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.chest.2020.03.056","article-title":"Development and clinical application of a prednisolone\/cortisol assay to determine adherence to maintenance oral prednisolone in severe asthma","volume":"158","author":"Mansur","year":"2020","journal-title":"Chest"},{"key":"10.1016\/j.rmcr.2021.101559_bib18","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0140-6736(12)60988-X","article-title":"Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial","volume":"380","author":"Pavord","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.rmcr.2021.101559_bib19","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"371","author":"Ortega","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.rmcr.2021.101559_bib20","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1403291","article-title":"Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma","volume":"371","author":"Bel","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.rmcr.2021.101559_bib21","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S2213-2600(17)30344-2","article-title":"Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies","volume":"6","author":"FitzGerald","year":"2018","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.rmcr.2021.101559_bib22","doi-asserted-by":"crossref","first-page":"1776468","DOI":"10.1080\/2331205X.2020.1776468","article-title":"Predictors of the enhanced response to mepolizumab treatment for severe eosinophilic asthma: a retrospective, long-term study","volume":"7","author":"Numata","year":"2020","journal-title":"Cogent Med."},{"key":"10.1016\/j.rmcr.2021.101559_bib23","first-page":"CD010834","article-title":"Anti\u2010IL5 therapies for asthma","volume":"9","author":"Farne","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.rmcr.2021.101559_bib24","doi-asserted-by":"crossref","first-page":"1902259","DOI":"10.1183\/13993003.02259-2019","article-title":"Adherence to inhaled corticosteroids and clinical outcomes in mepolizumab therapy for severe asthma","volume":"55","author":"d'Ancona","year":"2020","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.rmcr.2021.101559_bib25","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1111\/all.14693","article-title":"Benralizumab after sub-optimal response to mepolizumab in severe eosinophilic asthma","volume":"76","author":"Kavanagh","year":"2021","journal-title":"Allergy"},{"key":"10.1016\/j.rmcr.2021.101559_bib26","doi-asserted-by":"crossref","first-page":"605","DOI":"10.2147\/JAA.S270298","article-title":"Switch from IL-5 to IL-5-receptor \u03b1 antibody treatment in severe eosinophilic asthma","volume":"13","author":"Drick","year":"2020","journal-title":"J. Asthma Allergy"},{"key":"10.1016\/j.rmcr.2021.101559_bib27","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/resp.13730","article-title":"Rational oral corticosteroid use in adult severe asthma: a narrative review","volume":"25","author":"Chung","year":"2020","journal-title":"Respirology"},{"key":"10.1016\/j.rmcr.2021.101559_bib28","series-title":"Press release. GSK announces FDA approval for nucala (mepolizumab) for use in adults with chronic rhinosinusitis with nasal polyps","year":"2021"},{"key":"10.1016\/j.rmcr.2021.101559_bib29","article-title":"Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: A randomized, placebo-controlled trial","author":"Bachert","year":"2021","journal-title":"J. Allergy Clin. Immunol"},{"key":"10.1016\/j.rmcr.2021.101559_bib30","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S2213-2600(21)00097-7","article-title":"SYNAPSE study investigators, Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"9","author":"Han","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.rmcr.2021.101559_bib31","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1177\/1945892420978351","article-title":"Effect of benralizumab in patients with severe eosinophilic asthma and chronic rhinosinusitis with nasal polyps: a case series","volume":"35","author":"Chitguppi","year":"2021","journal-title":"Am. J. Rhinol. Allergy"},{"key":"10.1016\/j.rmcr.2021.101559_bib32","doi-asserted-by":"crossref","DOI":"10.1177\/2058738420950851","article-title":"Real-life effects of benralizumab on allergic chronic rhinosinusitis and nasal polyposis associated with severe asthma","volume":"34","author":"Lombardo","year":"2020","journal-title":"Int. J. Immunopathol. Pharmacol."},{"key":"10.1016\/j.rmcr.2021.101559_bib33","article-title":"Benralizumab improves symptoms of patients with severe, eosinophilic asthma with a diagnosis of nasal polyposis","author":"Canonica","year":"2021","journal-title":"Allergy"},{"key":"10.1016\/j.rmcr.2021.101559_bib34","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.jaci.2017.05.044","article-title":"Reduced need for surgery in severe nasal polyposis with mepolizumab: randomized trial","volume":"140","author":"Bachert","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"issue":"Suppl. S29","key":"10.1016\/j.rmcr.2021.101559_bib35","first-page":"1","article-title":"European position paper on rhinosinusitis and nasal polyps 2020","volume":"58","author":"Fokkens","year":"2020","journal-title":"Rhinology"},{"key":"10.1016\/j.rmcr.2021.101559_bib36","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1164\/rccm.201806-1182OC","article-title":"Medical Research Council UK Refractory Asthma Stratification Programme (RASP-UK), Remotely monitored therapy and nitric oxide suppression identifies nonadherence in severe asthma","volume":"199","author":"Heaney","year":"2019","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.rmcr.2021.101559_bib37","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1164\/rccm.202104-1040LE","article-title":"MRC UK Refractory Asthma Stratification programme (RASP-UK), FeNO non-suppression identifies corticosteroid-resistant type-2 signaling in severe asthma","volume":"204","author":"Couillard","year":"2021","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.rmcr.2021.101559_bib38","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/j.jaip.2020.11.060","article-title":"Successful pregnancy in the setting of eosinophil depletion by benralizumab","volume":"9","author":"Manetz","year":"2021","journal-title":"J. Allergy Clin. Immunol. Pract."}],"container-title":["Respiratory Medicine Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213007121002215?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213007121002215?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T01:04:23Z","timestamp":1761959063000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213007121002215"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":31,"alternative-id":["S2213007121002215"],"URL":"https:\/\/doi.org\/10.1016\/j.rmcr.2021.101559","relation":{},"ISSN":["2213-0071"],"issn-type":[{"value":"2213-0071","type":"print"}],"subject":[],"published":{"date-parts":[[2022]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of benralizumab in a patient with uncontrolled severe eosinophilic asthma and comorbid chronic rhinosinusitis with nasal polyps refractory to mepolizumab treatment","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmcr.2021.101559","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101559"}}